Physician profile
Eileen M Fox
NPI 1972692127
$1,269.06
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $407 · 2020: $308 · 2021: $478 · 2022: $75.51.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $230.86 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $192.73 | 2019-2022 | |
| Pfizer INC. | $175.66 | 2019-2021 | |
| Corium, LLC | $99.62 | 2021-2022 | |
| Tris Pharma INC | $98.55 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $77.56 | 2020-2021 | |
| Ucb, INC. | $76.25 | 2020-2021 | |
| Kaleo, INC. | $71.04 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $51.29 | 2021 | |
| Adlon Therapeutics L.P. | $41.75 | 2020-2021 | |
| Genentech USA, INC. | $28.23 | 2020-2021 | |
| Mission Pharmacal Company | $18.75 | 2019 | |
| Rhodes Pharmaceuticals L.P. | $18.58 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.14 | 2019 | |
| Alk-Abello, INC | $16.11 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $15.03 | 2021 | |
| Galderma Laboratories, L.P. | $14.60 | 2021 | |
| Sage Therapeutics, LLC | $13.88 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $11.43 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eileen Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.